Rejuvenate Biomed
- Biotech or pharma, therapeutic R&D
Rejuvenate Biomed is an AI-enabled, clinical-stage private biotech company decoding the biology of aging to develop synergistic combination therapeutics for age-related diseases.
Utilizing two proprietary drug discovery platforms, Rejuvenate Biomed has generated a robust pipeline of unique combination drugs targeting different age- related diseases.
RJx-01, has demonstrated significant potential in a Phase 1b trial as an oral treatment for sarcopenia.
Two Phase 2 trials for RJx- 01 in sarcopenia with readouts expected in 2026 and mid 2027 are being pursued:
- A double-blind, placebo-controlled trial in COPD patients suffering from acute and/or chronic sarcopenia - fully funded through an award from Wellcome Leap, a non-for-profit organization established by Wellcome Trust - has started.
- A double-blind, placebo-controlled phase 2 trial to investigate the effect of RJx-01 on GLP1 receptor agonist muscle-related pathologies is planned.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}